NC
DXCM icon

Nicholas Company’s DexCom DXCM Stock Holding History

Nicholas Company’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-965
Closed -$64.7K – 217
2024
Q3 		$64.7K Sell
965
-766,686
-100% -$63M ﹤0.01% 216
2024
Q2 		$87M Sell
767,651
-65
-0% -$8.22K 1.45% 8
2024
Q1 		$106M Sell
767,716
-74,595
-9% -$9.38M 1.76% 5
2023
Q4 		$105M Buy
842,311
+67,751
+9% +$6.92M 1.85% 6
2023
Q3 		$72.3M Buy
774,560
+275,515
+55% +$31.1M 1.45% 10
2023
Q2 		$64.1M Hold
499,045
– – 1.23% 21
2023
Q1 		$58M Hold
499,045
– – 1.18% 19
2022
Q4 		$56.5M Sell
499,045
-135
-0% -$14.8K 1.21% 18
2022
Q3 		$40.2M Buy
499,180
+40,280
+9% +$3.41M 0.92% 37
2022
Q2 		$34.2M Buy
458,900
+57,680
+14% +$5.26M 0.75% 52
2022
Q1 		$51.3M Sell
401,220
-80
-0% -$8.75K 0.92% 36
2021
Q4 		$53.9M Sell
401,300
-400
-0.1% -$57.5K 0.88% 41
2021
Q3 		$54.9M Sell
401,700
-40
-0% -$5.04K 0.97% 35
2021
Q2 		$42.9M Buy
401,740
+60,220
+18% +$5.78M 0.75% 49
2021
Q1 		$30.7M Sell
341,520
-1,600
-0.5% -$150K 0.57% 58
2020
Q4 		$31.7M Buy
+343,120
New +$30.6M 0.6% 58
2016
Q1 		– Sell
-78,560
Closed -$1.61M – 209
2015
Q4 		$1.61M Buy
78,560
+16,560
+27% +$345K 0.03% 191
2015
Q3 		$1.33M Sell
62,000
-28,000
-31% -$625K 0.03% 196
2015
Q2 		$1.8M Hold
90,000
– – 0.03% 199
2015
Q1 		$1.4M Hold
90,000
– – 0.03% 202
2014
Q4 		$1.24M Hold
90,000
– – 0.03% 215
2014
Q3 		$899K Hold
90,000
– – 0.02% 217
2014
Q2 		$892K Hold
90,000
– – 0.02% 221
2014
Q1 		$930K Sell
90,000
-191,460
-68% -$1.98M 0.02% 227
2013
Q4 		$2.49M Sell
281,460
-140,840
-33% -$1.11M 0.06% 219
2013
Q3 		$2.98M Sell
422,300
-60,800
-13% -$385K 0.08% 202
2013
Q2 		$2.71M Buy
+483,100
New +$2.31M 0.08% 203

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Nicholas Company's DXCM Position: Q4 2024 in Review

Nicholas Company sold out of DexCom (DXCM) in Q4 2024, closing a stake of 965 shares — an estimated $64.7K sold.

Nicholas Company first reported a position in DXCM in Q2 2013 and held it in 27 quarters. The position peaked at $106M in Q1 2024. 952 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

  • Nicholas Company reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
  • Nicholas Company sold 965 DexCom shares in Q4 2024, an estimated $64.7K.
  • Nicholas Company first reported a position in DexCom in Q2 2013 and held it in 27 quarters.
  • Nicholas Company's DexCom position peaked at $106M in Q1 2024.
  • 952 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Nicholas Company's 13F filing for Q4 2024, filed 10 Feb 2025.